<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Victoria Hendrick, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Keck, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H581521"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Euthymic bipolar patients often receive maintenance pharmacotherapy prior to conception and during pregnancy [<a href="#rid1">1,2</a>]. Onset of bipolar disorder in women typically occurs during childbearing years [<a href="#rid3">3</a>], and most patients are at risk for recurrent mood episodes [<a href="#rid2">2</a>].</p><p>This topic reviews preconception and prenatal maintenance pharmacotherapy for bipolar patients. Indications for maintenance pharmacotherapy during pregnancy, the teratogenic risks of medications used for bipolar disorder, preconception counseling and care for bipolar disorder, and the general maintenance treatment of bipolar disorder are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/82834.html" rel="external">"Bipolar disorder in women: Indications for preconception and prenatal maintenance pharmacotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/17159.html" rel="external">"Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15701.html" rel="external">"Bipolar disorder in women: Contraception and preconception assessment and counseling"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment"</a>.)</p><p></p><p class="headingAnchor" id="H581793"><span class="h1">DEFINITION OF BIPOLAR DISORDER</span><span class="headingEndMark"> — </span>Bipolar disorder is characterized by episodes of mania  (<a class="graphic graphic_table graphicRef91106" href="/d/graphic/91106.html" rel="external">table 1</a>), hypomania  (<a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 2</a>), and major depression  (<a class="graphic graphic_table graphicRef91398" href="/d/graphic/91398.html" rel="external">table 3</a>) [<a href="#rid4">4</a>]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic episodes, and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/d/html/14642.html" rel="external">"Bipolar disorder in adults: Clinical features"</a> and  <a class="medical medical_review" href="/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H4469121"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H259024962"><span class="h2">General principles</span><span class="headingEndMark"> — </span>Preconception and prenatal maintenance treatment for bipolar patients is usually provided by perinatal or general psychiatrists in collaboration with obstetricians and primary care clinicians [<a href="#rid5">5-8</a>].</p><p>After considering medical advice about the risks of fetal exposure to medications and the risks of avoiding preconception and prenatal maintenance pharmacotherapy, bipolar patients can choose to [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Maintain existing pharmacotherapy throughout conception, the pregnancy, and birth.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Switch medications before they try to conceive to avoid drugs with a greater risk of teratogenicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discontinue pharmacotherapy prior to conception and restart medications during the second or third trimester (when organogenesis is completed).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discontinue pharmacotherapy prior to conception and remain medication-free throughout conception, the pregnancy, and delivery.</p><p></p><p>For bipolar patients who plan to or do become pregnant, we suggest maintenance pharmacotherapy to prevent mood episodes, based upon prospective observational studies that found untreated pregnant patients were at increased risk of recurrent mood episodes [<a href="#rid1">1,10</a>], as well as our clinical experience and that of several authorities [<a href="#rid2">2,11-14</a>]. However, for patients with a mild lifetime course of illness, it is reasonable to try to avoid pharmacotherapy during pregnancy. Indications for preconception and prenatal maintenance pharmacotherapy, risks of avoiding maintenance pharmacotherapy, and specific drugs suggested as preconception and prenatal maintenance treatment are discussed separately. (See  <a class="medical medical_review" href="/d/html/82834.html" rel="external">"Bipolar disorder in women: Indications for preconception and prenatal maintenance pharmacotherapy"</a> and <a class="local">'Risks of avoiding pharmacotherapy'</a> below and <a class="local">'Choosing a specific maintenance treatment'</a> below.)</p><p>In prescribing preconception and prenatal maintenance pharmacotherapy, clinicians should attempt to use [<a href="#rid2">2,5,15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Drugs with fewer known teratogenic effects</p><p class="bulletIndent1"><span class="glyph">●</span>Monotherapy</p><p class="bulletIndent1"><span class="glyph">●</span>Doses at the low end of the therapeutic range</p><p></p><p>For euthymic bipolar patients who are receiving preconception or prenatal maintenance treatment with <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, a second-generation antipsychotic, or <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, we suggest continuing the same drug [<a href="#rid15">15,16</a>]. For patients who are currently treated with <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> or <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, we suggest switching treatment to avoid the teratogenic effects of these two antiepileptics [<a href="#rid11">11,17</a>]. (See <a class="local">'Switching from valproate or carbamazepine to less teratogenic drugs'</a> below and  <a class="medical medical_review" href="/d/html/2218.html" rel="external">"Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Effects of ASMs on the fetus and child'</a>.)</p><p>Female bipolar patients who want to conceive and continue maintenance treatment with <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> or <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> can consider in vitro fertilization and use of a gestational carrier [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/7431.html" rel="external">"Gestational carrier pregnancy"</a>.)</p><p>Medication doses generally need to be increased over the course of pregnancy, especially in the second and third trimesters, to prevent decreases in serum concentrations [<a href="#rid18">18-21</a>]. This is because pregnancy causes physiologic changes that alter pharmacokinetics (eg, increased extracellular fluid volume and body fat increase the volume of distribution, increased activity of hepatic enzymes increases metabolism, and increased renal blood flow and glomerular filtration rate increase renal elimination).</p><p>Recurrent bipolar mood episodes may occur despite preconception or prenatal maintenance pharmacotherapy because of problems with adherence [<a href="#rid9">9</a>]. Suggestions for improving adherence are discussed separately. (See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment", section on 'Second-line'</a>.)</p><p class="headingAnchor" id="H1046366"><span class="h2">Risk of adverse pregnancy and birth outcomes</span><span class="headingEndMark"> — </span>The risk of adverse pregnancy and birth outcomes in women with bipolar disorder who receive pharmacotherapy and women with bipolar disorder who are not treated with pharmacotherapy is discussed separately. (See  <a class="medical medical_review" href="/d/html/15701.html" rel="external">"Bipolar disorder in women: Contraception and preconception assessment and counseling", section on 'Risk of pregnancy complications'</a>.) </p><p class="headingAnchor" id="H55179445"><span class="h2">Teratogenic and postnatal risks of pharmacotherapy</span><span class="headingEndMark"> — </span>Following the first trimester, the risk of teratogenesis decreases and it is safer to prescribe drug combinations and higher doses. The teratogenic and postnatal risks of medications commonly used to treat bipolar disorder are discussed separately. (See  <a class="medical medical_review" href="/d/html/17159.html" rel="external">"Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"</a>.)</p><p class="headingAnchor" id="H259025003"><span class="h2">Risks of avoiding pharmacotherapy</span><span class="headingEndMark"> — </span>For bipolar patients who are receiving preconception or prenatal maintenance pharmacotherapy, discontinuing treatment includes the following risks [<a href="#rid1">1,10,12,17,22</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>It is not known if maintenance drugs that are discontinued provide the same level of prophylactic efficacy after they are restarted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stopping treatment may increase the risk of recurrent mood episodes, particularly if medications are discontinued abruptly (eg, in less than two weeks). (See  <a class="medical medical_review" href="/d/html/15701.html" rel="external">"Bipolar disorder in women: Contraception and preconception assessment and counseling", section on 'Relapse after discontinuing pharmacotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treating recurrent episodes during pregnancy may be difficult and expose the fetus to more medications at higher doses compared with pharmacologic maintenance of euthymia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postpartum mood episodes may occur more frequently in patients who are not treated with maintenance pharmacotherapy during pregnancy. A meta-analysis of eight prospective and retrospective observational studies found that postpartum mood episodes occurred in more patients who were medication free during pregnancy (n = 385), compared with patients who used prophylactic pharmacotherapy during pregnancy (n = 60; 66 versus 23 percent) [<a href="#rid23">23</a>].</p><p></p><p class="headingAnchor" id="H259027145"><span class="h2">Switching from valproate or carbamazepine to less teratogenic drugs</span><span class="headingEndMark"> — </span>For bipolar patients who plan to become pregnant, are treated with <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> or <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, and are clinically stable (eg, euthymic for at least six months), we suggest that clinicians attempt to switch maintenance treatment to other drugs [<a href="#rid11">11,24</a>]. Valproate and carbamazepine are generally regarded as teratogens, primarily based upon observational studies of epilepsy patients [<a href="#rid2">2,5,25,26</a>]. In addition, prenatal exposure to these medications, particularly valproate, is associated with developmental delay and lower intelligence quotient scores [<a href="#rid27">27,28</a>]. Specific drugs suggested as preconception and prenatal maintenance treatment and the teratogenic effects of valproate and carbamazepine are discussed separately. (See <a class="local">'Choosing a specific maintenance treatment'</a> below and  <a class="medical medical_review" href="/d/html/2218.html" rel="external">"Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Effects of ASMs on the fetus and child'</a>.)</p><p>For bipolar patients who plan to become pregnant and decide to switch from maintenance treatment with <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> or <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> to a less teratogenic drug, we suggest changing pharmacotherapy at least three to six months before patients try to conceive, to assess the effectiveness of the new medication. Valproate or carbamazepine are tapered and discontinued over 15 to 30 days; this approach appears to be associated with a lower risk of recurrence than a faster taper [<a href="#rid1">1</a>]. The medication is tapered by the same amount for each dose decrease. As an example, valproate 2000 mg per day is decreased by 250 to 500 mg per day, every three to seven days. At the same time, the new medication is started and titrated up.</p><p>However, alternative medications may not work as well as <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> or <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, and switching medications can precipitate a recurrence of bipolar mood symptoms [<a href="#rid29">29</a>]. Thus, for patients with a history of poor outcomes using other medications, such as <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>, and <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, it is reasonable to maintain valproate or carbamazepine, rather than switching to another medication. Patients treated with valproate or carbamazepine during pregnancy should also receive high doses of <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> (eg, 4 to 5 mg per day), although the efficacy of folate supplementation in reducing the risk of neural tube defects is not clear [<a href="#rid30">30</a>]. Managing pregnant patients who receive valproate or carbamazepine is discussed separately in the context of epilepsy, including the use of folic acid. (See  <a class="medical medical_review" href="/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period", section on 'Management during pregnancy'</a> and  <a class="medical medical_review" href="/d/html/423.html" rel="external">"Preconception and prenatal folic acid supplementation", section on 'Maternal use of antiseizure medications'</a>.)</p><p>For bipolar patients who are maintained on <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> or <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> and unexpectedly become pregnant, we suggest switching medications. (See <a class="local">'Unplanned pregnancies'</a> below.)</p><p class="headingAnchor" id="H7573636"><span class="h2">Monitoring patients</span><span class="headingEndMark"> — </span>Bipolar patients receiving preconception or prenatal maintenance pharmacotherapy should be regularly monitored for recurrence of manic and depressive symptoms as well as medication side effects. Particular attention is given to suicidal ideation and to psychotic symptoms. Stable patients can be seen every one to two months. For patients who remit from an acute mood episode and remain stable, monitoring can be tapered, with progressively longer intervals between assessments. As an example, a patient who is seen every two weeks at the time of remission can be seen every two weeks for one to three more visits, then every one to two months until parturition. More frequent visits should be scheduled for patients who develop symptoms or side effects; monitoring acutely ill patients is discussed separately. (See  <a class="medical medical_review" href="/d/html/14647.html" rel="external">"Bipolar disorder in pregnant women: Screening, diagnosis, and choosing treatment for mania and hypomania", section on 'Monitoring patients'</a>.)</p><p class="headingAnchor" id="H55180124"><span class="h2">Adjunctive psychotherapy</span><span class="headingEndMark"> — </span>For bipolar patients who receive preconception or prenatal maintenance pharmacotherapy, we suggest adjunctive psychoeducation or cognitive-behavioral therapy (CBT), based upon randomized trials that excluded pregnant patients. Although no head-to-head trials have compared these psychotherapies, we generally choose psychoeducation because there are more data supporting its use, it is easier to administer than CBT and thus usually more available, and psychoeducation is generally an element of CBT. The evidence of efficacy for reducing recurrent mood episodes with other psychotherapies, such as family therapy and interpersonal and social rhythm therapy, is not as strong. (See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment", section on 'Choosing adjunctive psychotherapy'</a>.)</p><p class="headingAnchor" id="H51186202"><span class="h1">CHOOSING A SPECIFIC MAINTENANCE TREATMENT</span><span class="headingEndMark"> — </span>There are no randomized trials in bipolar patients who plan to or do become pregnant to guide preconception and prenatal maintenance pharmacotherapy; the benefits and risks of treatment are thus based upon randomized trials that excluded pregnant patients [<a href="#rid31">31-33</a>], as well as observational studies, birth registries, and clinical experience [<a href="#rid18">18</a>].</p><p>For euthymic bipolar patients who are receiving preconception or prenatal maintenance treatment with <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, a second-generation antipsychotic, or <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, we suggest continuing the same drug (see <a class="local">'General principles'</a> above). For euthymic bipolar patients who plan to or do become pregnant and are not receiving preconception or prenatal maintenance treatment, we suggest maintenance treatment according to the sequence described in the subsections below. Patients initially receive first line therapy and progress through each step until they respond.</p><p class="headingAnchor" id="H328635"><span class="h2">First line</span><span class="headingEndMark"> — </span>For euthymic bipolar patients who plan to or do become pregnant, we suggest <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> as first line maintenance treatment [<a href="#rid5">5</a>], based upon randomized trials that excluded pregnant patients. There are more data supporting the efficacy of lamotrigine for the general maintenance treatment of bipolar disorder compared with <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> and <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>. In addition, a prospective observational study of euthymic, pregnant bipolar patients found that relapse occurred in significantly fewer patients who continued lamotrigine (n = 10) than patients who stopped pharmacotherapy (n = 16; 30 versus 100 percent) [<a href="#rid10">10</a>]. A second study of eight pregnant bipolar patients who received maintenance treatment with lamotrigine found that at delivery, the infants were full term, healthy, and without congenital malformations; in addition, none of the infants developed a rash [<a href="#rid34">34</a>]. The reproductive safety profile of lamotrigine is generally regarded as favorable [<a href="#rid5">5,25,35</a>], and there is more experience using lamotrigine during pregnancy compared with quetiapine and risperidone. Although there are more data supporting the efficacy of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> than lamotrigine for the general maintenance treatment of bipolar disorder, the reproductive safety of lamotrigine is generally regarded as comparable or superior to lithium.</p><p>Serum concentrations of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> should be measured prior to conception or as soon as possible in patients who present during pregnancy [<a href="#rid34">34</a>]. Concentrations are regularly monitored (eg, every four weeks) during pregnancy and the dose adjusted accordingly. Serum-level-to-dose ratios generally decrease during the first trimester due to increased drug clearance, and reach their lowest level during the third trimester. A dose increase of 20 to 25 percent from preconception baseline is often required to maintain baseline serum concentrations and euthymia.</p><p>After delivery, clearance of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> decreases and thus decreased doses are frequently necessary to maintain baseline serum concentrations and avoid toxicity. (See  <a class="medical medical_review" href="/d/html/83170.html" rel="external">"Bipolar disorder in postpartum women: Treatment", section on 'Patients not breastfeeding'</a>.)</p><p>Evidence for the efficacy of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>, and <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> for delaying or preventing bipolar mood episodes is discussed separately, as are the reproductive safety profile of these drugs, and the dose schedule, side effect profile, and pharmacology of lamotrigine. (See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment"</a> and  <a class="medical medical_review" href="/d/html/17159.html" rel="external">"Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"</a> and  <a class="medical medical_review" href="/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Lamotrigine'</a>.)</p><p class="headingAnchor" id="H328643"><span class="h2">Resistant patients</span><span class="headingEndMark"> — </span>Maintenance treatment for bipolar disorder with <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> is often not efficacious, based upon randomized trials (which excluded pregnant patients) [<a href="#rid31">31</a>]. For resistant bipolar patients who do not respond to or tolerate preconception or prenatal maintenance lamotrigine, we suggest <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> or <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>, based upon their efficacy and adverse effects in randomized trials that excluded pregnant patients [<a href="#rid32">32,36</a>]. (Response is defined as psychopathology that is considerably less than full criteria for a mood episode, eg, no more than two moderately or three mildly intense symptoms.) No head-to-head trials have compared quetiapine and risperidone. The specific choice is thus based upon other factors, including past response to medications, side effect profiles, comorbid general medical conditions, patient preference, and cost.</p><p>Although there are more data supporting the maintenance efficacy of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> than <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> or <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>, study findings suggest that quetiapine and risperidone are not associated with an increased risk of major malformations [<a href="#rid37">37-40</a>], whereas lithium is generally regarded as teratogenic [<a href="#rid24">24,41,42</a>]. In addition, the preference for treating pregnant bipolar patients with quetiapine or risperidone rather than lithium is consistent with practice guidelines from the United Kingdom National Institute for Health and Clinical Excellence [<a href="#rid9">9,43</a>]. However, second generation antipsychotics may cause metabolic complications. (See <a class="local">'Metabolic complications'</a> below.)</p><p>To switch drugs, <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> is tapered and discontinued over one to two weeks while at the same time <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> or <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> is started and titrated up. We generally taper lamotrigine by the same amount for each dose decrease. As an example, lamotrigine 200 mg per day is decreased by 50 mg per day, every two to three days.</p><p>For resistant bipolar patients who do not respond to preconception or prenatal maintenance treatment with either <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> or <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>, we suggest tapering and discontinuing the failed medication over one to two weeks while at the same time the other drug is started and titrated up. The failed medication is generally tapered by the same amount for each dose decrease.</p><p>The efficacy of <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> and <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> for the general maintenance treatment of bipolar disorder is discussed separately, as is the dose, side effect profile  (<a class="graphic graphic_table graphicRef82533" href="/d/graphic/82533.html" rel="external">table 4</a>), pharmacology, and reproductive safety profile. (See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment"</a> and  <a class="medical medical_review" href="/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a> and  <a class="medical medical_review" href="/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects"</a> and  <a class="medical medical_review" href="/d/html/17159.html" rel="external">"Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Second-generation'</a>.)</p><p class="headingAnchor" id="H22544288"><span class="h3">Metabolic complications</span><span class="headingEndMark"> — </span>Second-generation antipsychotics may cause hyperglycemia [<a href="#rid44">44</a>]. In pregnant women with diabetes, hyperglycemia is associated with increased risks of spontaneous abortion, congenital malformations, and macrosomia. (See  <a class="medical medical_review" href="/d/html/94859.html" rel="external">"Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management"</a>.)</p><p>In addition, second-generation antipsychotics may cause obesity [<a href="#rid44">44,45</a>]. Obesity during pregnancy is associated with an increased risk of multiple obstetric complications, including gestational diabetes mellitus and pre-eclampsia. (See  <a class="medical medical_review" href="/d/html/433.html" rel="external">"Obesity in pregnancy: Complications and maternal management"</a>.) Although many clinicians use second-generation antipsychotics during pregnancy [<a href="#rid46">46</a>], some authorities generally avoid them due to concerns about excessive weight gain and gestational diabetes [<a href="#rid25">25,26,47</a>]. A review of observational studies (primarily case reports) found that gestational diabetes mellitus has been observed in patients who have taken <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">clozapine</a>, <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, or <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> [<a href="#rid48">48</a>].</p><p>Clinicians using second-generation antipsychotics in pregnant patients should manage potential metabolic complications by monitoring [<a href="#rid9">9,24,43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Weight gain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood pressure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fasting serum glucose, cholesterol, and triglyceride concentrations. The normal reference range for cholesterol and triglycerides is generally higher in pregnant women compared with nonpregnant individuals  (<a class="graphic graphic_table graphicRef81137" href="/d/graphic/81137.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/d/html/417.html" rel="external">"Normal reference ranges for laboratory values in pregnancy"</a>.)</p><p></p><p>Patients are assessed at baseline and every one to three months during pregnancy [<a href="#rid17">17,24</a>]. In addition, a glucose tolerance test is performed every four months. (See  <a class="medical medical_review" href="/d/html/6797.html" rel="external">"Gestational diabetes mellitus: Screening, diagnosis, and prevention"</a>.)</p><p class="headingAnchor" id="H328730"><span class="h2">Refractory patients</span><span class="headingEndMark"> — </span>Based upon clinical experience, many bipolar patients do not respond to or tolerate sequential trials of preconception or prenatal maintenance <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, and <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>. (Response is defined as psychopathology that is considerably less than full criteria for a mood episode, eg, no more than two moderately or three mildly intense symptoms.) For these refractory patients, we suggest <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> [<a href="#rid11">11,17</a>]. Evidence for the efficacy of lithium includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Randomized trials (that excluded pregnant patients) have demonstrated the benefit of maintenance treatment with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> in bipolar disorder; these trials are discussed separately. (See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment", section on 'Lithium'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A prospective observational study found that relapse occurred in fewer pregnant bipolar patients who continued pharmacotherapy (n = 27, 85 percent received <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>) than patients who stopped pharmacotherapy (n = 62; 37 versus 86 percent) [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A prospective observational study found that relapse occurred half as often in pregnant bipolar patients who received maintenance pharmacotherapy (n = 31, 97 percent received <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>) than patients who did not (n = 10; 19 versus 40 percent) [<a href="#rid15">15</a>].</p><p></p><p>Use of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> in pregnant patients with bipolar disorder who do not respond to antipsychotics is consistent with practice guidelines from the United Kingdom National Institute for Health and Care Excellence [<a href="#rid49">49</a>].</p><p>Although <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> is generally regarded as teratogenic due to increased risks of cardiac defects (eg, Ebstein anomaly) [<a href="#rid24">24,41,42</a>], many authorities consider the absolute risk small [<a href="#rid5">5,25,26,50</a>]. For pregnant patients using lithium, we suggest prenatal screening for anomalies with high-resolution ultrasonography at 16 to 18 weeks gestation, and depending upon the results, fetal echocardiography, which can aid decisions about pregnancy termination, referral for delivery at a hospital with the appropriate level of neonatal care, and postnatal interventions for congenital malformations [<a href="#rid8">8,26,51</a>]. The teratogenic effects of lithium are discussed separately. (See  <a class="medical medical_review" href="/d/html/17159.html" rel="external">"Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Lithium'</a>.)</p><p>For pregnant patients treated with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, we suggest using the lowest amount necessary to achieve a therapeutic serum concentration [<a href="#rid41">41,52</a>]. The total daily dose is often given in two to three divided doses (rather than a single daily dose) using controlled release preparations, to avoid high peak serum levels [<a href="#rid15">15,53,54</a>]; however, it is not known whether this reduces the risk of teratogenic effects [<a href="#rid53">53</a>]. Serum lithium concentrations are checked every two to four weeks during pregnancy, until 36 weeks gestation, at which point levels should be checked weekly [<a href="#rid7">7,24,55</a>]. The dose schedule for lithium, use of serum concentrations to establish the proper dose, and lithium toxicity are discussed separately. (See  <a class="medical medical_review" href="/d/html/15317.html" rel="external">"Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects"</a>.)</p><p>Additional laboratory monitoring of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> includes thyroid and renal function tests that are checked at baseline and repeated every three months [<a href="#rid24">24</a>]. Normal reference ranges for laboratory tests often differ for gravid and nongravid patients  (<a class="graphic graphic_table graphicRef81137" href="/d/graphic/81137.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/d/html/417.html" rel="external">"Normal reference ranges for laboratory values in pregnancy"</a>.)</p><p>Serum <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentrations generally decrease during pregnancy and the doses required to effectively prevent bipolar mood episodes thus increase [<a href="#rid2">2,19</a>]. These changes are a consequence of increases in maternal glomerular filtration rate and extracellular fluid volume and their impact upon pharmacokinetics. As an example, renal excretion of lithium may increase 30 to 100 percent [<a href="#rid41">41,54,55</a>]. During the second and third trimesters, twice the prepregnancy dose of lithium may be required to achieve therapeutic serum concentrations [<a href="#rid53">53</a>]. In addition, serum lithium concentrations can be altered by concomitant medications and other clinical factors (eg, diarrhea). (See  <a class="medical medical_review" href="/d/html/15317.html" rel="external">"Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Prescribing lithium'</a>.)</p><p>Frequent urination, thirst, weight gain, and nausea are common during pregnancy and can be exacerbated by <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>. Side effects of lithium are discussed separately. (See  <a class="medical medical_review" href="/d/html/15317.html" rel="external">"Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Managing lithium adverse effects'</a>.)</p><p>For pregnant patients treated with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, delivery should occur in facilities with the ability to resuscitate neonates, given the risks of postnatal complications [<a href="#rid24">24</a>]. Postnatal toxicity and withdrawal secondary to lithium are discussed separately. (See  <a class="medical medical_review" href="/d/html/17159.html" rel="external">"Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Lithium'</a>.)</p><p>To avoid <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity, we suggest withholding lithium for one to two days before a scheduled delivery or at the onset of labor, consistent with the practice of many perinatal psychiatrists [<a href="#rid7">7,20,56</a>]. Although a brief reduction in serum lithium concentrations may possibly precipitate a postpartum relapse, the risk seems small. In a prospective observational study of nine pregnant bipolar patients treated with lithium in the third trimester, lithium was withheld for one to two days before a scheduled delivery or at the onset of labor; maternal serum concentrations decreased from a mean of 0.8 mEq/L (0.8 mmol/L) to 0.5 mEq/L (0.5 mmol/L), and none of the patients became symptomatic [<a href="#rid56">56</a>]. However, rather than withholding lithium as a means of avoiding lithium toxicity, it is reasonable to increase hydration close to the time of delivery [<a href="#rid20">20</a>].</p><p>For pregnant patients treated with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, adequate hydration must be maintained throughout labor, especially if the serum level drawn at the time of delivery is high. During labor and delivery, vascular volume can decrease through loss of blood as well as diaphoresis [<a href="#rid19">19</a>]. If oral intake is insufficient to maintain adequate hydration, adjunctive intravenous fluids are used to prevent dehydration and lithium toxicity [<a href="#rid7">7,17</a>].</p><p>After delivery, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> is resumed when patients are medically stable (provided breastfeeding is not planned) at doses lower than those used during the third trimester, because maternal glomerular filtration rates rapidly decrease to pregravid levels [<a href="#rid56">56,57</a>]. Patients treated with lithium prior to conception are restarted on the prepregnancy dose. Patients not treated with lithium prior to conception are usually started at a dose of 600 to 900 mg per day, which is then increased by 300 to 600 mg every one to five days based upon response, tolerability, and body mass index. Serum concentrations are measured 24 hours after delivery and every three to five days until they stabilize at a therapeutic level. (See  <a class="medical medical_review" href="/d/html/15317.html" rel="external">"Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Lithium dose and serum concentrations'</a>.)</p><p>The newborn should be monitored for symptoms of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity for up to 10 days after delivery [<a href="#rid41">41,57</a>], even if the maternal serum lithium concentration at delivery is within normal limits. Signs of neonatal toxicity at the time of delivery should prompt a cord serum level [<a href="#rid24">24</a>] and a neonatal electrocardiogram [<a href="#rid41">41,57</a>]. Neonatal lithium toxicity and withdrawal are discussed separately. (See  <a class="medical medical_review" href="/d/html/17159.html" rel="external">"Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Lithium'</a>.)</p><p>For pregnant bipolar patients who do not respond to prenatal maintenance pharmacotherapy, become acutely ill, and respond to an acute course of electroconvulsive therapy (ECT), we suggest maintenance ECT. Support for this approach comes from small observational studies that suggest ECT may be efficacious for pregnant bipolar patients and appears to be safe for perinatal patients. [<a href="#rid58">58</a>]. The efficacy and safety of using ECT in bipolar patients who are pregnant, as well as the technique, are discussed separately. (See  <a class="medical medical_review" href="/d/html/14647.html" rel="external">"Bipolar disorder in pregnant women: Screening, diagnosis, and choosing treatment for mania and hypomania", section on 'Refractory patients'</a> and  <a class="medical medical_review" href="/d/html/17159.html" rel="external">"Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy", section on 'Electroconvulsive therapy'</a> and  <a class="medical medical_review" href="/d/html/1712.html" rel="external">"Technique for performing electroconvulsive therapy (ECT) in adults", section on 'Pregnancy'</a>.)</p><p class="headingAnchor" id="H14312316"><span class="h1">UNPLANNED PREGNANCIES</span><span class="headingEndMark"> — </span>Unintended pregnancies in bipolar patients are common and may precipitate mood episodes. Two prospective observational studies of pregnant bipolar patients (n = 89 and 26) found that the pregnancy was not planned in 34 and 58 percent, and that unplanned pregnancy was associated with recurrent prenatal mood episodes [<a href="#rid1">1,10</a>].</p><p>For euthymic bipolar patients who unintentionally become pregnant during maintenance treatment with <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, a second-generation antipsychotic, or <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, we suggest continuing the same drug [<a href="#rid15">15,16</a>].</p><p>For bipolar patients who are maintained on <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> or <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> and unexpectedly become pregnant, we suggest switching medications. We typically titrate up the new drug as rapidly as tolerated, and then taper and discontinue the antiepileptic over the course of a few days. The antiepileptic is decreased the same amount for each dose reduction. As an example, valproate 1500 mg per day is decreased by 500 mg every one to two days. The choice of a new drug is discussed elsewhere in this topic, as is management of patients who decline switching medications. (See <a class="local">'Choosing a specific maintenance treatment'</a> above and <a class="local">'Switching from valproate or carbamazepine to less teratogenic drugs'</a> above.)</p><p>Bipolar patients who unexpectedly become pregnant may decide to discontinue maintenance pharmacotherapy. However, stopping medications (particularly over a period of less than two weeks) may increase the risk of recurrent mood episodes. (See  <a class="medical medical_review" href="/d/html/15701.html" rel="external">"Bipolar disorder in women: Contraception and preconception assessment and counseling", section on 'Relapse after discontinuing pharmacotherapy'</a>.)</p><p>Determining the gestational age will inform the decision to use maintenance pharmacotherapy in bipolar patients with unplanned pregnancies. The period of greatest risk for the teratogenic effects of medications is between the third and eighth week of gestation (weeks of gestation are counted from the first day of the last menstrual period)  (<a class="graphic graphic_figure graphicRef65816" href="/d/graphic/65816.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef56642" href="/d/graphic/56642.html" rel="external">figure 2</a>). Many unplanned pregnancies are discovered after this period of greatest risk has passed [<a href="#rid59">59</a>]; thus, discontinuing or switching treatment at this point often puts the mother at risk for relapse of a mood episode and provides minimal benefit to the fetus [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H1340392"><span class="h1">FOLIC ACID SUPPLEMENTATION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">Folic acid</a> is recommended for every woman planning to conceive a child and is discussed separately. (See  <a class="medical medical_review" href="/d/html/423.html" rel="external">"Preconception and prenatal folic acid supplementation"</a> and  <a class="medical medical_review" href="/d/html/453.html" rel="external">"Nutrition in pregnancy: Dietary requirements and supplements", section on 'Folate/folic acid'</a> and  <a class="medical medical_review" href="/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period", section on 'Folic acid supplementation'</a>.)</p><p class="headingAnchor" id="H1532686368"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115361.html" rel="external">"Society guideline links: Bipolar disorder"</a>.)</p><p class="headingAnchor" id="H13499509"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15348.html" rel="external">"Patient education: Bipolar disorder (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16338.html" rel="external">"Patient education: Coping with high drug prices (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/4869.html" rel="external">"Patient education: Bipolar disorder (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/16279.html" rel="external">"Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"</a>)</p><p></p><p>These educational materials can be used as part of psychoeducational psychotherapy. (See  <a class="medical medical_review" href="/d/html/14666.html" rel="external">"Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies", section on 'Group psychoeducation'</a>.)</p><p>The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment of bipolar disorder in a booklet entitled "Bipolar Disorder," which is available online at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nimh.nih.gov%2Fhealth%2Fpublications%2Fbipolar-disorder&amp;token=c9TXCEotcdMcarRyXBEnhwgIEx3THC4PwSF2z%2FRKFh%2B8HmGSkeqm5bDBx4bOcfNh0qAPwOVFAtZ6twY6hM0vtq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=16971" target="_blank">their website</a> or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.</p><p>More comprehensive information is provided in many books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002); An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison, PhD (published by Random House, 1995); and Treatment of Bipolar Illness: A Casebook for Clinicians and Patients, by RM Post, MD, and GS Leverich, LCSW (published by Norton Press, 2008).</p><p>The Depression and Bipolar Support Alliance (available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.dbsalliance.org%2F&amp;token=ZAuWdG5s4GIvjFnkWRP6rC6dBWU8%2FMZEcwGeeAm5c58EpMgcvhu2s4%2FQc68YQejm&amp;TOPIC_ID=16971" target="_blank">their website</a> or 800-826-3632) is a national organization that educates members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.</p><p>The National Alliance on Mental Illness (available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nami.org%2Fhome&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F2HxKa%2BxiiO3Jy683P2iZQzyCfYwDkCHhxD3GR9NIJSW&amp;TOPIC_ID=16971" target="_blank">their website</a> or 800-950-6264) is a similarly structured organization devoted to education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.</p><p class="headingAnchor" id="H1340835"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition of bipolar disorder</strong> – Bipolar disorder is characterized by episodes of mania  (<a class="graphic graphic_table graphicRef91106" href="/d/graphic/91106.html" rel="external">table 1</a>), hypomania  (<a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 2</a>), and major depression  (<a class="graphic graphic_table graphicRef91398" href="/d/graphic/91398.html" rel="external">table 3</a>). (See <a class="local">'Definition of bipolar disorder'</a> above and  <a class="medical medical_review" href="/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prescribing maintenance pharmacotherapy</strong> – Bipolar disorder is a highly recurrent illness. For bipolar patients who plan to or do become pregnant, we suggest maintenance pharmacotherapy rather than no treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, for patients with a mild lifetime course of illness, it is reasonable to try to avoid pharmacotherapy during pregnancy. (See <a class="local">'General principles'</a> above and  <a class="medical medical_review" href="/d/html/82834.html" rel="external">"Bipolar disorder in women: Indications for preconception and prenatal maintenance pharmacotherapy"</a> and <a class="local">'Risks of avoiding pharmacotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoiding teratogens</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In prescribing preconception or prenatal maintenance pharmacotherapy for bipolar patients, clinicians should attempt to use drugs with fewer known teratogenic effects, monotherapy, and doses at the low end of the therapeutic range. Following the first trimester, the risk of teratogenesis decreases and it is safer to prescribe drug combinations and higher doses. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">Valproate</a> and <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> are generally regarded as teratogens. For stable bipolar patients who plan to or do become pregnant and are currently treated with valproate and carbamazepine, we suggest switching treatment to a less teratogenic drug rather than maintaining valproate or carbamazepine (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, it is reasonable to maintain valproate or carbamazepine for patients with a history of poor outcomes using other medications. (See <a class="local">'Switching from valproate or carbamazepine to less teratogenic drugs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choosing a specific maintenance treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>First line – For bipolar patients who plan to or do become pregnant, we suggest <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> as first line maintenance treatment rather than other medications (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'First line'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Resistant patients – For patients who are unresponsive to or intolerant of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, we suggest <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> or <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> rather than other medications (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Resistant patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Refractory patients – For refractory patients who do not respond to sequential maintenance treatment trials with <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, and <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> is a reasonable option. Although lithium is generally regarded as teratogenic due to increased risks of cardiac defects, the absolute risk is considered low. Maintenance ECT may help patients unresponsive to maintenance pharmacotherapy. (See <a class="local">'Refractory patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unplanned pregnancies</strong> – For bipolar patients with unplanned pregnancies, determining the gestational age will inform the decision to use maintenance pharmacotherapy. The period of greatest risk for the teratogenic effects of medications is between the third and eighth week of gestation  (<a class="graphic graphic_figure graphicRef65816" href="/d/graphic/65816.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef56642" href="/d/graphic/56642.html" rel="external">figure 2</a>). (See <a class="local">'Unplanned pregnancies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">Folic acid</a><strong> supplements</strong> – Every woman planning to conceive a child should receive folic acid. (See  <a class="medical medical_review" href="/d/html/423.html" rel="external">"Preconception and prenatal folic acid supplementation"</a> and  <a class="medical medical_review" href="/d/html/453.html" rel="external">"Nutrition in pregnancy: Dietary requirements and supplements", section on 'Folate/folic acid'</a> and  <a class="medical medical_review" href="/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period", section on 'Folic acid supplementation'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Viguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007; 164:1817.</a></li><li><a class="nounderline abstract_t">Sharma V, Sharma P, Sharma S. Managing bipolar disorder during pregnancy and the postpartum period: a critical review of current practice. Expert Rev Neurother 2020; 20:373.</a></li><li><a class="nounderline abstract_t">Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64:543.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</li><li><a class="nounderline abstract_t">ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008; 111:1001. Reaffirmed Obstet Gynecol 2018; 131:185. Reaffirmed 2020.</a></li><li><a class="nounderline abstract_t">Jones I, Craddock N. Bipolar disorder and childbirth: the importance of recognising risk. Br J Psychiatry 2005; 186:453.</a></li><li><a class="nounderline abstract_t">Galbally M, Snellen M, Lewis AJ. A review of the use of psychotropic medication in pregnancy. Curr Opin Obstet Gynecol 2011; 23:408.</a></li><li><a class="nounderline abstract_t">Burt VK, Bernstein C, Rosenstein WS, Altshuler LL. Bipolar disorder and pregnancy: maintaining psychiatric stability in the real world of obstetric and psychiatric complications. Am J Psychiatry 2010; 167:892.</a></li><li class="breakAll">National Institute for Health and Clinical Excellence. Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Clinical Practice Guideline Number 38, 2006. http://www.nice.org.uk/ (Accessed on March 07, 2012).</li><li><a class="nounderline abstract_t">Newport DJ, Stowe ZN, Viguera AC, et al. Lamotrigine in bipolar disorder: efficacy during pregnancy. Bipolar Disord 2008; 10:432.</a></li><li><a class="nounderline abstract_t">Cohen LS. Treatment of bipolar disorder during pregnancy. J Clin Psychiatry 2007; 68 Suppl 9:4.</a></li><li><a class="nounderline abstract_t">Viguera AC, Cohen LS, Baldessarini RJ, Nonacs R. Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can J Psychiatry 2002; 47:426.</a></li><li><a class="nounderline abstract_t">Gentile S. Bipolar disorder in pregnancy: to treat or not to treat? BMJ 2012; 345:e7367.</a></li><li><a class="nounderline abstract_t">Clark CT, Wisner KL. Treatment of Peripartum Bipolar Disorder. Obstet Gynecol Clin North Am 2018; 45:403.</a></li><li><a class="nounderline abstract_t">Bergink V, Bouvy PF, Vervoort JS, et al. Prevention of postpartum psychosis and mania in women at high risk. Am J Psychiatry 2012; 169:609.</a></li><li><a class="nounderline abstract_t">Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 2010; 36:518.</a></li><li class="breakAll">Burt VK, Stein K. Treatment of women. In: The American Psychiatric Publishing Textbook of Psychiatry, Fifth Edition, Hales RE, Yodofsky SC, Gabbard GO (Eds), American Psychiatric Publishing, Inc., Washington, DC 2008. p.1489.</li><li class="breakAll">Frey BN, Macritchie KA, Soares CN, Steiner M. Bipolar disorder in women. In: Bipolar Disorder: Clinical and Neurobiological Foundations, Yatham LN, Maj M (Eds), Wiley-Blackwell, West Sussex 2010. p.463.</li><li class="breakAll">Newport DJ, Fernandez SV, Juric S, Stowe ZN. Psychopharmacology during pregnancy and lactation. In: The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc., Washington, D.C. 2009. p.1373.</li><li><a class="nounderline abstract_t">Deligiannidis KM, Byatt N, Freeman MP. Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. J Clin Psychopharmacol 2014; 34:244.</a></li><li><a class="nounderline abstract_t">Payne JL. Psychopharmacology in Pregnancy and Breastfeeding. Psychiatr Clin North Am 2017; 40:217.</a></li><li class="breakAll">Goodwin FK, Jamison KR. Maintenance medical treatment. In: Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression, 2nd edition, Oxford University Press, New York 2007. p.797.</li><li><a class="nounderline abstract_t">Wesseloo R, Kamperman AM, Munk-Olsen T, et al. Risk of Postpartum Relapse in Bipolar Disorder and Postpartum Psychosis: A Systematic Review and Meta-Analysis. Am J Psychiatry 2016; 173:117.</a></li><li><a class="nounderline abstract_t">Galbally M, Snellen M, Walker S, Permezel M. Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. Aust N Z J Psychiatry 2010; 44:99.</a></li><li><a class="nounderline abstract_t">Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry 2011; 24:34.</a></li><li><a class="nounderline abstract_t">Cohen LS, Wang B, Nonacs R, et al. Treatment of mood disorders during pregnancy and postpartum. Psychiatr Clin North Am 2010; 33:273.</a></li><li><a class="nounderline abstract_t">Cummings C, Stewart M, Stevenson M, et al. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child 2011; 96:643.</a></li><li><a class="nounderline abstract_t">Baker GA, Bromley RL, Briggs M, et al. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology 2015; 84:382.</a></li><li><a class="nounderline abstract_t">Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23:346.</a></li><li><a class="nounderline abstract_t">Jentink J, Bakker MK, Nijenhuis CM, et al. Does folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid? Pharmacoepidemiol Drug Saf 2010; 19:803.</a></li><li><a class="nounderline abstract_t">Smith LA, Cornelius V, Warnock A, et al. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 2007; 9:394.</a></li><li><a class="nounderline abstract_t">Weisler RH, Nolen WA, Neijber A, et al. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 2011; 72:1452.</a></li><li><a class="nounderline abstract_t">Cipriani A, Rendell JM, Geddes J. Olanzapine in long-term treatment for bipolar disorder. Cochrane Database Syst Rev 2009; :CD004367.</a></li><li><a class="nounderline abstract_t">Clark CT, Klein AM, Perel JM, et al. Lamotrigine dosing for pregnant patients with bipolar disorder. Am J Psychiatry 2013; 170:1240.</a></li><li><a class="nounderline abstract_t">Marangell LB. Current issues: women and bipolar disorder. Dialogues Clin Neurosci 2008; 10:229.</a></li><li><a class="nounderline abstract_t">Quiroz JA, Yatham LN, Palumbo JM, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010; 68:156.</a></li><li><a class="nounderline abstract_t">Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 2009; 15:183.</a></li><li><a class="nounderline abstract_t">Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 2007; 164:1214.</a></li><li><a class="nounderline abstract_t">Coppola D, Russo LJ, Kwarta RF Jr, et al. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf 2007; 30:247.</a></li><li><a class="nounderline abstract_t">Huybrechts KF, Hernández-Díaz S, Patorno E, et al. Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA Psychiatry 2016; 73:938.</a></li><li><a class="nounderline abstract_t">Jain AE, Lacy T. Psychotropic drugs in pregnancy and lactation. J Psychiatr Pract 2005; 11:177.</a></li><li><a class="nounderline abstract_t">Kloos AL, Dubin-Rhodin A, Sackett JC, et al. The impact of mood disorders and their treatment on the pregnant woman, the fetus, and the infant. Curr Psychiatry Rep 2010; 12:96.</a></li><li class="breakAll">National Institute for Health and Clinical Excellence. NICE clinical guideline 45. Antenatal and postnatal mental health: Clinical management and service guidance. April 2007 http://www.nice.org.uk/CG045 (Accessed on January 01, 2012).</li><li><a class="nounderline abstract_t">De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011; 8:114.</a></li><li><a class="nounderline abstract_t">Choong E, Bondolfi G, Etter M, et al. Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. J Psychiatr Res 2012; 46:540.</a></li><li><a class="nounderline abstract_t">Yonkers KA, Vigod S, Ross LE. Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. Obstet Gynecol 2011; 117:961.</a></li><li><a class="nounderline abstract_t">Bodén R, Lundgren M, Brandt L, et al. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry 2012; 69:715.</a></li><li><a class="nounderline abstract_t">Gentile S. Pregnancy exposure to second-generation antipsychotics and the risk of gestational diabetes. Expert Opin Drug Saf 2014; 13:1583.</a></li><li class="breakAll">National Institute for Health and Care Excellence (NICE). Antenatal and postnatal mental health: clinical management and service guidance. NICE clinical guideline 192. December 2014. http://www.nice.org.uk/guidance/cg192 (Accessed on August 27, 2015).</li><li><a class="nounderline abstract_t">Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153:592.</a></li><li><a class="nounderline abstract_t">Diav-Citrin O, Shechtman S, Tahover E, et al. Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. Am J Psychiatry 2014; 171:785.</a></li><li><a class="nounderline abstract_t">Patorno E, Huybrechts KF, Bateman BT, et al. Lithium Use in Pregnancy and the Risk of Cardiac Malformations. N Engl J Med 2017; 376:2245.</a></li><li class="breakAll">Stewart DE, Vigod SN, Stotland NL. Obstetrics and gynecology. In: The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL (Ed), American Psychiatric Publishing, Inc, Washington, DC 2011. p.797.</li><li class="breakAll">Janicak PG, Marder SR, Pavuluri MN. Principles and Practice of Psychopharmacotherapy, Fifth Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.367.</li><li><a class="nounderline abstract_t">Deligiannidis KM. Therapeutic drug monitoring in pregnant and postpartum women: recommendations for SSRIs, lamotrigine, and lithium. J Clin Psychiatry 2010; 71:649.</a></li><li><a class="nounderline abstract_t">Newport DJ, Viguera AC, Beach AJ, et al. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry 2005; 162:2162.</a></li><li><a class="nounderline abstract_t">Menon SJ. Psychotropic medication during pregnancy and lactation. Arch Gynecol Obstet 2008; 277:1.</a></li><li><a class="nounderline abstract_t">Bulut M, Bez Y, Kaya MC, et al. Electroconvulsive therapy for mood disorders in pregnancy. J ECT 2013; 29:e19.</a></li><li><a class="nounderline abstract_t">Freeman MP. Bipolar disorder and pregnancy: risks revealed. Am J Psychiatry 2007; 164:1771.</a></li></ol></div><div id="topicVersionRevision">Topic 16971 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18056236" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32172610" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Managing bipolar disorder during pregnancy and the postpartum period: a critical review of current practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485606" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485606" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18378767" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15928351" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Bipolar disorder and childbirth: the importance of recognising risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21897237" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A review of the use of psychotropic medication in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20693466" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bipolar disorder and pregnancy: maintaining psychiatric stability in the real world of obstetric and psychiatric complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20693466" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bipolar disorder and pregnancy: maintaining psychiatric stability in the real world of obstetric and psychiatric complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18402631" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Lamotrigine in bipolar disorder: efficacy during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17764378" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Treatment of bipolar disorder during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12085677" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Managing bipolar disorder during pregnancy: weighing the risks and benefits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23144175" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Bipolar disorder in pregnancy: to treat or not to treat?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30092918" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment of Peripartum Bipolar Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22407083" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevention of postpartum psychosis and mania in women at high risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18787227" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Antipsychotic therapy during early and late pregnancy. A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18787227" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Antipsychotic therapy during early and late pregnancy. A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18787227" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Antipsychotic therapy during early and late pregnancy. A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18787227" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Antipsychotic therapy during early and late pregnancy. A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24525634" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28477649" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Psychopharmacology in Pregnancy and Breastfeeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28477649" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Psychopharmacology in Pregnancy and Breastfeeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26514657" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Risk of Postpartum Relapse in Bipolar Disorder and Postpartum Psychosis: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20113298" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21088587" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Drug treatment for mood disorders in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20385337" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Treatment of mood disorders during pregnancy and postpartum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21415043" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25540307" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19329543" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20680999" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Does folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17547586" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22054050" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19160237" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Olanzapine in long-term treatment for bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24185239" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Lamotrigine dosing for pregnant patients with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18689292" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Current issues: women and bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20227682" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19461391" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Use and safety of antipsychotic drugs during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671284" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17343431" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27540849" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15920391" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Psychotropic drugs in pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20425293" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The impact of mood disorders and their treatment on the pregnant woman, the fetus, and the infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20425293" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The impact of mood disorders and their treatment on the pregnant woman, the fetus, and the infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22009159" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22316639" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422871" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22752236" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25189088" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pregnancy exposure to second-generation antipsychotics and the risk of gestational diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25189088" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pregnancy exposure to second-generation antipsychotics and the risk of gestational diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8615404" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24781368" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28591541" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Lithium Use in Pregnancy and the Risk of Cardiac Malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28591541" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Lithium Use in Pregnancy and the Risk of Cardiac Malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28591541" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Lithium Use in Pregnancy and the Risk of Cardiac Malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20492855" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Therapeutic drug monitoring in pregnant and postpartum women: recommendations for SSRIs, lamotrigine, and lithium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16263858" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17710428" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Psychotropic medication during pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23519218" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Electroconvulsive therapy for mood disorders in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18056226" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Bipolar disorder and pregnancy: risks revealed.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
